Gennova is India’s only company to deploy the mRNA platform to develop a vaccine, HGC019, against the novel coronavirus. HGC019 has already demonstrated safety, immunogenicity and neutralization antibody activity in rodents and non-human primate models. Further to its animal toxicity studies, Gennova is now gearing up to take the vaccine to the next step of clinical study. Apart from this, Gennova is also using the mRNA platform to create vaccines against Zika, rabies and Zoster which are in the pre-clinical stage.
What are mRNA vaccines?
In a standard viral vaccine, either inactivated (or attenuated) virus or viral proteins known to cause the infection are used for immunization. However, an mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus. The host body uses this to produce the viral protein that is recognized by the immune system, thereby making the body ready to fight against the disease.